APA (7th ed.) Citation

Kurtz, D. M., Chabon, J. J., Soo, J., Co Ting Keh, L., Alig, S., Schultz, A., . . . Alizadeh, A. A. (2021). Phased variants improve DLBCL minimal residual disease detection at the end of therapy. Journal of clinical oncology, 39(15_suppl), 7565. https://doi.org/10.1200/JCO.2021.39.15_suppl.7565

Chicago Style (17th ed.) Citation

Kurtz, David Matthew, et al. "Phased Variants Improve DLBCL Minimal Residual Disease Detection at the End of Therapy." Journal of Clinical Oncology 39, no. 15_suppl (2021): 7565. https://doi.org/10.1200/JCO.2021.39.15_suppl.7565.

MLA (9th ed.) Citation

Kurtz, David Matthew, et al. "Phased Variants Improve DLBCL Minimal Residual Disease Detection at the End of Therapy." Journal of Clinical Oncology, vol. 39, no. 15_suppl, 2021, p. 7565, https://doi.org/10.1200/JCO.2021.39.15_suppl.7565.